In Case You Missed It, Johnson & Johnson Is Undergoing a Major Business Transformation
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is what you might call a staple stock. It's a common holding for growth, value, and income investors given that many of the products it sells are inelastic. In other words, you can't determine when you get sick, or what ailment you develop, meaning there's always demand for medical devices, pharmaceuticals, and some of J&J's consumer health products, regardless of how well or poorly the U.S. economy is performing.
Johnson & Johnson is also revered for its pristine credit rating -- it and Microsoft are the only two publicly traded companies to hold Standard & Poor's highest credit rating, AAA -- and the fact that it's increased its dividend for 55 consecutive years. You can count on two hands how many companies have a longer active streak. This consistency is why investors, young and old, have bought Johnson & Johnson in their investment portfolios and simply forgotten about it.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Aktie
Johnson & Johnson erfreut sich großer Beliebtheit, mit einer hohen Zahl an Buy- und niedriger Zahl an Sell-Einschätzungen.
Das Kursziel von 194 € für Johnson & Johnson impliziert eine deutliche Steigerung um über 20% gegenüber 148.28 €.
